Fig. 3From: Developing the latest framework to measure and incentivise pharmaceutical industry contributions to health research and developmentThe 2016 Index found that late-stage research and development projects conducted in partnership included at least one access provision more often than in-house projects (63% versus 41% of projects, respectively). Companies reported seven types of access provisions that aim to address a range of barriers to access in low- and middle-income countries [3]Back to article page